Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Imipramine
Drug ID BADD_D01139
Description Imipramine, the prototypical tricyclic antidepressant (TCA), is a dibenzazepine-derivative TCA. TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, imipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, imipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as imipramine and amitriptyline, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also block histamine H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively [A6584]. Imipramine has less sedative and anticholinergic effects than the tertiary amine TCAs, amitriptyline and clomipramine. Imipramine may be used to treat depression and nocturnal enuresis in children [FDA Label]. Unlabeled indications include chronic and neuropathic pain (including diabetic neuropathy), panic disorder, attention-deficit/hyperactivity disorder (ADHD), and post-traumatic stress disorder (PTSD) [L1349,L1348,A31900,L1351,L1352,L1353,A31904].
Indications and Usage May also be used off-label to manage panic disorders with or without agoraphobia, as a second line agent for ADHD in children and adolescents, to manage bulimia nervosa, for short-term management of acute depressive episodes in bipolar disorder and schizophrenia, for the treatment of acute stress disorder and posttraumatic stress disorder, and for symptomatic treatment of postherpetic neuralgia and painful diabetic neuropathy [L1349,L1348,A31900,L1351,L1352,L1353,A31904].
Marketing Status Prescription; Discontinued
ATC Code N06AA02
DrugBank ID DB00458
KEGG ID D08070
MeSH ID D007099
PubChem ID 3696
TTD Drug ID D06ZUK
NDC Product Code Not Available
Synonyms Imipramine | Norchlorimipramine | Imidobenzyle | Imizin | Tofranil | Janimine | Melipramine | Pryleugan | Imipramine Pamoate | 4,4'-Methylenebis(3-hydroxy-2-naphthoic acid)-3-(10,11-dihydro-5H-dibenzo(b,f)azepin-5-yl)-N,N-dimethyl-1-propanamine (1:2) | Imipramine Hydrochloride | Imipramine Monohydrochloride
Chemical Information
Molecular Formula C19H24N2
CAS Registry Number 50-49-7
SMILES CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Motor dysfunction17.02.10.0040.001869%Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Ill-defined disorder08.01.03.049--Not Available
Inner ear disorder04.04.02.002--Not Available
Blood disorder01.05.01.004--Not Available
Psychotic disorder19.03.01.002--
Hepatobiliary disease09.01.08.003--Not Available
Bone marrow failure01.03.03.005--
Floppy iris syndrome12.02.02.001; 06.05.03.007; 17.02.11.0010.001869%Not Available
The 6th Page    First    Pre   6    Total 6 Pages